SCHEMBL63435

SCHEMBL63435

O=C(NCc1ccc(F)cc1)c1nc2n(c(=O)c1O)CC1CC2CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
CYP2C9 P11712 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
CALCA P06881 1/20 0.38
CNR2 P34972 1/20 0.37
ERCC1 P07992 1/20 0.37
FEN1 P39748 1/20 0.37
ERCC4 Q92889 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TRPC3 Q13507 1/20 0.36
TRPC7 Q9HCX4 1/20 0.36
GRIN2B Q13224 1/20 0.36
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51828 0.81 SMN1; SMN2 (0.37) SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL61799 0.81 KCNH2 (0.56) KCNH2CYP2C9SMN1; SMN2L3MBTL1CALCA
SCHEMBL13691554 0.81 KCNH2 (0.55) KCNH2CYP2C9SMN1; SMN2CALCAERCC1
SCHEMBL62329 0.79 KCNH2 (0.51) KCNH2CYP2C9SMN1; SMN2CALCAERCC1
SCHEMBL62276 0.78 CYP2C9 (0.50) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL5120385 0.77 ALDH1A1 (0.43) KCNH2CYP2C9L3MBTL1LMNAMAPT
SCHEMBL5580009 0.76 CYP2C9 (0.46) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL13691532 0.76 KCNH2 (0.48) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL5127826 0.76 GRIN2B (0.47) CYP2C9SMN1; SMN2L3MBTL1LMNAMAPT
SCHEMBL1150712 0.75 KCNE1 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885SMN1; SMN2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.